Welcome to our dedicated page for Pavmed SEC filings (Ticker: PAVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PAVmed Inc. SEC filings document its medical technology business, subsidiary operations and capital structure. Form 8-K reports cover operating results, business updates, Regulation FD disclosures, material agreements and Nasdaq listing-compliance matters for the company and its medical device, diagnostics and digital health activities.
Proxy statements and stockholder-meeting filings describe governance, voting matters and authorization of share issuances tied to preferred stock, warrants and convertible debt. Recent capital-structure disclosures include Series D Convertible Preferred Stock, warrants to purchase preferred stock, redemption of Series C Preferred Stock, and refinancing of a senior secured convertible note.
PAVmed Inc. ownership disclosure: Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi report beneficial ownership of 657,219 shares of Common Stock, representing 9.99% of the class as of March 31, 2026. The reported total includes 461,539 shares held by Two Seas Global (Master) Fund LP and 195,680 shares issuable upon exercise of warrants within 60 days, calculated against 6,383,089 shares outstanding on that date.
The filing states that Two Seas Capital has sole voting and dispositive power over the shares and warrants through its advisory and GP roles, and that the percentage figures give effect to a beneficial ownership limitation. Signatures indicate the statement was filed on behalf of the three reporting persons.
PAVmed Inc. reported first quarter 2026 results and a broad business update across its medical device, diagnostics, and digital health businesses. Revenue was $22 thousand, while operating expenses were about $8.1 million, leading to a GAAP net loss attributable to common stockholders of roughly $7.0 million, or $(4.42) per diluted share.
On a non-GAAP basis, PAVmed reported an adjusted loss of about $1.9 million, or $(1.17) per share. Cash and cash equivalents were $6.5 million as of March 31, 2026, up from $1.5 million at year-end 2025. Subsidiary Lucid Diagnostics recognized $1.3 million in EsoGuard test revenue, processed 3,177 tests, raised approximately $17 million through an underwritten offering, and ended the quarter with $45 million in pro forma cash, extending its runway into 2027.
Management highlighted Veris Health’s progress toward an FDA 510(k) submission for its implantable physiological monitor and deeper commercial engagement with The Ohio State University’s James Cancer Hospital. PAVmed also emphasized its simplified capital structure, strengthened balance sheet, and the advancement of its relaunched medical device portfolio, including the PortIO vascular access device and endoscopic esophageal imaging technology.
PAVmed Inc. reported first-quarter 2026 results showing minimal revenue and ongoing losses while relying heavily on financing transactions. Revenue for the three months ended March 31, 2026 was $22,000, against operating expenses of $8.1 million, leading to an operating loss of $8.0 million. After fair value gains on investments and debt and a large deemed dividend on preferred stock, net loss attributable to common stockholders was about $7.0 million, or $(4.42) per basic and diluted share.
To strengthen liquidity, PAVmed issued $30 million of Series D Convertible Preferred Stock and a new $15.0 million senior secured convertible note, refinanced prior convertible debt, redeemed its Series C preferred stock, and converted the Series D into 4,615,393 common shares. Cash increased to $6.5 million at March 31, 2026 from $1.5 million at year-end, and working capital was approximately $3.8 million. However, management disclosed that recurring losses, low revenues and dependence on additional capital raise substantial doubt about the company’s ability to continue as a going concern over the next year.
PAVmed Inc. ownership disclosure: First Manhattan Co. LLC, FMC Group Holdings LP and First Manhattan Management LLC report beneficial ownership of 639,191 shares of Common Stock, representing 9.6% of the class as of 03/31/2026. The cover page shows sole voting power 638,720 and shared voting power 471 for each filer.
PAVMED INC. holders report beneficial ownership totaling 709,069 shares (9.99%). The filing states the 709,069 shares include 49 shares, 500,000 Restricted Common Stock and 209,020 shares issuable upon exercise of warrants and conversion of notes. Percentages use 6,383,089 shares outstanding as of March 27, 2026. Holdings are reported as of March 31, 2026 and the issuable shares are subject to a 9.99% beneficial ownership blocker.
PAVmed Inc. is calling a virtual annual stockholder meeting on June 24, 2026 at 10:00 a.m. Eastern. Stockholders will elect two Class A directors, approve amendments to the Employee Stock Purchase Plan (ESPP), and ratify CBIZ CPAs P.C. as independent auditor for 2026.
The ESPP proposal would raise shares available under the plan to 215,774 and increase the annual “evergreen” limit for future increases to up to 500,000 shares each January 1 through 2031. As of the April 27, 2026 record date, 7,272,739 shares of common stock were outstanding and eligible to vote.
PAVmed Inc. registered 9,230,786 shares of common stock for resale by selling stockholders, consisting of 4,615,393 shares issued upon conversion of Series D preferred and 4,615,393 shares issuable upon exercise of related warrants. The company is not selling shares here and will not receive proceeds from resales; it may receive up to $30,000,000 to the extent the Warrants are exercised. The registration covers resale by the listed selling stockholders and permits the shares to be sold on exchanges, OTC or by negotiated transactions, at the selling holders' discretion.
PAVmed Inc. files a registration statement to permit resale of 9,230,786 shares of common stock by selling stockholders. The shares consist of 4,615,393 shares issued upon conversion of Series D preferred stock and 4,615,393 shares issuable upon exercise of warrants tied to that private placement. The company is not selling shares here and will receive proceeds only if the warrants are exercised — up to $30,000,000 — with proceeds intended for working capital and general corporate purposes. The prospectus discloses the Series D conversion price of $6.50 per share, a warrant exercise mechanism that may deliver common shares in lieu of preferred, and a callable feature tied to MolDx publication of a draft Medicare local coverage determination.